FGFR3 and neoplasm: For tumours of the Ta pathway, the frequency of TP53 mutations seems to increase gradually with stage, from pTa (11/219; 5% of tumours with FGFR3 mutations also have TP53 mutations) to pT1 (29/106; TP53 mutations in 27% of tumours) and pT2-4 tumours (10/24; TP53 mutations in 42% of tumours).